Eculizumab as first-line treatment for patients with severe presentation of complement factor H antibody–mediated hemolytic uremic syndrome - Coccia, Paula A.; Alconcher, Laura F.; Ferraris, Veronica; Lucarelli, Lucas I.; Grillo, Maria A.; Arias, Maria Andrea; Saurit, Mariana; Ratto, Viviana M.; dos Santos, Celia; Sánchez-Luceros, Analía (Pediatric nephrology (Berlin, West), 2025)
Keywords: Antibodies; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - therapeutic use; Apheresis; Child; Children; Complement factor H; Complement Factor H - immunology; Complement Inactivating Agents - therapeutic use; Complement system; Dialysis; Female; Hemolytic uremic syndrome; Hemolytic-Uremic Syndrome - blood; Hemolytic-Uremic Syndrome - diagnosis; Hemolytic-Uremic Syndrome - drug therapy; Hemolytic-Uremic Syndrome - immunology; Humans; Immunosuppression; Immunosuppressive agents; Immunosuppressive Agents - therapeutic use; Immunotherapy; Kidney diseases; Male; Medicine; Medicine & Public Health; Monoclonal antibodies; Mycophenolate mofetil; Mycophenolic acid; Nephrology; Original Article; Pediatrics; Plasmapheresis; Prednisone; Renal Dialysis; Retrospective Studies; Rituximab; Thrombotic microangiopathy; Treatment Outcome; Urology; Eculizumab; Thrombotic microangiopathy; Complement factor H; Atypical HUS; Anti-factor H antibodies; Complement-mediated HUS